MX346201B - Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. - Google Patents
Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.Info
- Publication number
- MX346201B MX346201B MX2013005849A MX2013005849A MX346201B MX 346201 B MX346201 B MX 346201B MX 2013005849 A MX2013005849 A MX 2013005849A MX 2013005849 A MX2013005849 A MX 2013005849A MX 346201 B MX346201 B MX 346201B
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- treatment
- methods
- activity
- inhibitors
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41668910P | 2010-11-23 | 2010-11-23 | |
| PCT/US2011/061769 WO2012071374A1 (en) | 2010-11-23 | 2011-11-22 | Methods of treatment using selective bcl-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005849A MX2013005849A (es) | 2013-07-05 |
| MX346201B true MX346201B (es) | 2017-03-09 |
Family
ID=45218888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000835A MX377232B (es) | 2010-11-23 | 2011-11-22 | Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. |
| MX2013005849A MX346201B (es) | 2010-11-23 | 2011-11-22 | Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000835A MX377232B (es) | 2010-11-23 | 2011-11-22 | Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. |
Country Status (36)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| NZ608274A (en) | 2010-10-29 | 2015-05-29 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| SG190361A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| MY165884A (en) | 2010-11-23 | 2018-05-18 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| WO2013090645A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| CN111437386A (zh) | 2012-09-07 | 2020-07-24 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| US20150241429A1 (en) * | 2012-09-11 | 2015-08-27 | Hospital For Special Surgery | Irhom2 inhibition for the treatment of complement mediated disorders |
| TWI735759B (zh) | 2013-03-13 | 2021-08-11 | 愛爾蘭商艾伯維愛爾蘭無限公司 | 細胞凋亡誘導劑之中間體及其製備方法 |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼｃガンマ２及び耐性に関連した変異 |
| US11331328B2 (en) * | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
| DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| CA2995374A1 (en) | 2015-08-10 | 2017-02-16 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to bet bromodomain inhibitors |
| US10959993B2 (en) | 2015-11-03 | 2021-03-30 | Genentech, Inc. | Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer |
| EP3445452A4 (en) * | 2016-04-21 | 2019-10-30 | BioVentures, LLC | COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF |
| LT3494115T (lt) | 2016-08-05 | 2021-01-25 | The Regents Of The University Of Michigan | N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai |
| ES3028360T3 (en) * | 2017-06-26 | 2025-06-19 | Shenzhen Targetrx Inc | Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof |
| US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
| WO2019139900A1 (en) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| US20190328729A1 (en) | 2018-04-26 | 2019-10-31 | Emory University | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto |
| AU2019314819A1 (en) | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| TWI752335B (zh) | 2018-07-31 | 2022-01-11 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途 |
| UA125241C2 (uk) | 2018-07-31 | 2022-02-02 | Есентейдж Фарма (Сучжоу) Ко., Лтд. | СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP |
| US12097194B2 (en) | 2018-09-18 | 2024-09-24 | Signalchem Lifesciences Corporation | Combination therapy for treating blood cancer |
| SG11202104322YA (en) | 2018-10-29 | 2021-05-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor |
| CN113825754B (zh) | 2019-05-24 | 2023-09-22 | 正大天晴药业集团股份有限公司 | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 |
| WO2021078301A1 (zh) * | 2019-10-24 | 2021-04-29 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN113444078B (zh) * | 2020-03-25 | 2023-07-07 | 中国科学院上海有机化学研究所 | 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用 |
| CN115916822A (zh) | 2020-04-24 | 2023-04-04 | 基因泰克公司 | 使用抗CD79b免疫缀合物的方法 |
| EP4129998A4 (en) | 2020-04-29 | 2024-05-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor |
| CN114073707A (zh) * | 2020-08-21 | 2022-02-22 | 苏州亚盛药业有限公司 | 治疗系统性红斑狼疮的组合物和方法 |
| KR20230159524A (ko) * | 2021-03-19 | 2023-11-21 | 에일 테라퓨틱스 인코포레이티드 | Bcl-2 저해제로서 ((3-나이트로페닐)설포닐)아세트아마이드를 갖는 화합물 |
| US20250319183A1 (en) | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| CN117377672A (zh) | 2021-06-04 | 2024-01-09 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类化合物的磷酸酯 |
| IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
| WO2024102890A2 (en) * | 2022-11-11 | 2024-05-16 | The Board Of Regents Of The University Of Texas System | Amino acid-benzoic acid oligomers and methods of use thereof for treating cancer |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| ES2214546T3 (es) | 1995-09-15 | 2004-09-16 | PHARMACIA & UPJOHN COMPANY | N-oxidos de aminoariloxazolidinona. |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| KR20010083092A (ko) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
| EP1100496A4 (en) * | 1998-07-21 | 2002-10-23 | Univ Jefferson | SMALL PROTEIN INHIBITOR MOLECULES BCL-2 |
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| CA2395772C (en) | 1999-12-28 | 2010-09-28 | Eisai Co., Ltd. | Sulfonamide-containing heterocyclic compounds |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| AU2002259204B2 (en) | 2001-06-06 | 2008-01-17 | Eli Lilly And Company | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| US20090247613A1 (en) | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2003212500B2 (en) | 2002-02-26 | 2008-01-03 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound ZD1839 |
| IL163642A0 (en) | 2002-02-26 | 2005-12-18 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| TWI262077B (en) | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| PL1768967T3 (pl) | 2004-07-20 | 2009-09-30 | Symed Labs Ltd | Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne |
| US20060078617A1 (en) | 2004-08-27 | 2006-04-13 | Fritz Schueckler | Pharmaceutical compositions for the treatment of cancer |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| ES2345629T3 (es) | 2005-05-16 | 2010-09-28 | Irm Llc | Derivados de pirrolopiridina como inhibidores de proteina quinasas. |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TWI473808B (zh) | 2005-06-22 | 2015-02-21 | Plexxikon Inc | 用於激酶調節的化合物及方法及其適應症 |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| EP1957082B1 (en) | 2005-12-02 | 2012-04-11 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| WO2008030836A2 (en) | 2006-09-05 | 2008-03-13 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| WO2008124878A1 (en) | 2007-04-13 | 2008-10-23 | Cryptopharma Pty Ltd | Non-steroidal compounds |
| AU2008242703B2 (en) | 2007-04-19 | 2011-08-18 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009039553A1 (en) * | 2007-09-27 | 2009-04-02 | The Walter And Eliza Hall Institute Of Medical Research | Benzothiazole compounds |
| CN101883586A (zh) * | 2007-10-01 | 2010-11-10 | 约翰斯霍普金斯大学 | 使用环磷酰胺治疗神经性自身免疫疾病 |
| EP2197957A1 (en) | 2007-10-01 | 2010-06-23 | Arkema, Inc. | Blends of biodegradable polymers and acrylic copolymers |
| US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| WO2009052443A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| US20090176785A1 (en) | 2007-11-16 | 2009-07-09 | Abbott Laboratories | Method of treating arthritis |
| US20090149461A1 (en) | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Method of treating cancer |
| CN101481363B (zh) * | 2008-01-10 | 2011-05-04 | 江苏豪森药业股份有限公司 | 一种制备瑞格列奈的方法 |
| RU2502800C2 (ru) | 2008-01-15 | 2013-12-27 | Эббви Инк. | Усовершенствованные векторы экспрессии млекопитающих и их применение |
| EP2296664A1 (en) * | 2008-04-15 | 2011-03-23 | Burnham Institute for Medical Research | An inhibitor of anti-apoptotic proteins |
| MX2011003740A (es) | 2008-10-07 | 2011-05-02 | Astrazeneca Uk Ltd | Formulacion farmaceutica - 514. |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) * | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CA2744711C (en) * | 2008-12-05 | 2017-06-27 | Abbott Laboratories | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| WO2010077740A2 (en) | 2008-12-09 | 2010-07-08 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
| US20120094963A1 (en) | 2008-12-23 | 2012-04-19 | of Queen Elizabeth near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
| AU2010204555B2 (en) | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PL2511264T3 (pl) | 2009-01-19 | 2015-08-31 | Abbvie Inc | Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PE20120345A1 (es) | 2009-05-26 | 2012-05-17 | Abbvie Bahamas Ltd | Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| NZ608274A (en) | 2010-10-29 | 2015-05-29 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| SG190361A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| MY165884A (en) * | 2010-11-23 | 2018-05-18 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
-
2011
- 2011-11-22 MY MYPI2013700925A patent/MY165884A/en unknown
- 2011-11-22 SG SG2013040167A patent/SG190399A1/en unknown
- 2011-11-22 SI SI201131050A patent/SI2642999T1/sl unknown
- 2011-11-22 JP JP2013541010A patent/JP5876067B2/ja not_active Expired - Fee Related
- 2011-11-22 EP EP11793928.0A patent/EP2642999B1/en active Active
- 2011-11-22 KR KR1020137016217A patent/KR101841084B1/ko not_active Expired - Fee Related
- 2011-11-22 RS RS20161159A patent/RS55545B1/sr unknown
- 2011-11-22 BR BR112013012854-2A patent/BR112013012854B1/pt not_active IP Right Cessation
- 2011-11-22 RU RU2013128544/14A patent/RU2593231C2/ru active
- 2011-11-22 MY MYPI2017000882A patent/MY191300A/en unknown
- 2011-11-22 TW TW100142779A patent/TWI535701B/zh not_active IP Right Cessation
- 2011-11-22 PL PL11793928T patent/PL2642999T3/pl unknown
- 2011-11-22 PH PH1/2013/501006A patent/PH12013501006A1/en unknown
- 2011-11-22 UA UAA201307893A patent/UA113157C2/uk unknown
- 2011-11-22 NZ NZ708508A patent/NZ708508A/en not_active IP Right Cessation
- 2011-11-22 SG SG10201509631SA patent/SG10201509631SA/en unknown
- 2011-11-22 US US13/301,898 patent/US20120129853A1/en not_active Abandoned
- 2011-11-22 NZ NZ610746A patent/NZ610746A/en not_active IP Right Cessation
- 2011-11-22 ES ES11793928.0T patent/ES2603129T3/es active Active
- 2011-11-22 ES ES16153335T patent/ES2701603T3/es active Active
- 2011-11-22 MX MX2017000835A patent/MX377232B/es unknown
- 2011-11-22 MX MX2013005849A patent/MX346201B/es active IP Right Grant
- 2011-11-22 AR ARP110104338A patent/AR083946A1/es unknown
- 2011-11-22 UY UY0001033746A patent/UY33746A/es not_active Application Discontinuation
- 2011-11-22 KR KR1020187007228A patent/KR20180030257A/ko not_active Ceased
- 2011-11-22 HU HUE11793928A patent/HUE031267T2/en unknown
- 2011-11-22 CN CN201180065747.XA patent/CN103402521B/zh not_active Expired - Fee Related
- 2011-11-22 DK DK11793928.0T patent/DK2642999T3/en active
- 2011-11-22 EP EP16153335.1A patent/EP3028702B1/en active Active
- 2011-11-22 TW TW105100832A patent/TWI620736B/zh not_active IP Right Cessation
- 2011-11-22 PT PT117939280T patent/PT2642999T/pt unknown
- 2011-11-22 CN CN201610007260.0A patent/CN105664164B/zh not_active Expired - Fee Related
- 2011-11-22 KR KR1020197027331A patent/KR20190109590A/ko not_active Withdrawn
- 2011-11-22 WO PCT/US2011/061769 patent/WO2012071374A1/en not_active Ceased
- 2011-11-22 AU AU2011332000A patent/AU2011332000B2/en not_active Ceased
- 2011-11-22 LT LTEP11793928.0T patent/LT2642999T/lt unknown
- 2011-11-22 UA UAA201607110A patent/UA119150C2/uk unknown
- 2011-11-22 HR HRP20161762TT patent/HRP20161762T1/hr unknown
- 2011-11-22 CA CA2820618A patent/CA2820618C/en not_active Expired - Fee Related
-
2013
- 2013-05-16 ZA ZA2013/03589A patent/ZA201303589B/en unknown
- 2013-05-21 IL IL226490A patent/IL226490A/en active IP Right Grant
- 2013-05-22 GT GT201300136A patent/GT201300136A/es unknown
- 2013-05-22 CL CL2013001458A patent/CL2013001458A1/es unknown
- 2013-06-07 CR CR20130268A patent/CR20130268A/es unknown
- 2013-06-21 EC ECSP13012710 patent/ECSP13012710A/es unknown
-
2014
- 2014-11-06 US US14/535,070 patent/US9345702B2/en active Active
-
2016
- 2016-01-19 JP JP2016007618A patent/JP6215368B2/ja not_active Expired - Fee Related
- 2016-04-22 US US15/136,582 patent/US9872861B2/en active Active
- 2016-05-20 PH PH12016500939A patent/PH12016500939B1/en unknown
- 2016-06-27 AU AU2016204396A patent/AU2016204396B2/en not_active Ceased
- 2016-12-13 CY CY20161101289T patent/CY1118442T1/el unknown
-
2017
- 2017-03-03 DO DO2017000056A patent/DOP2017000056A/es unknown
- 2017-04-20 IL IL251845A patent/IL251845B/en active IP Right Grant
- 2017-12-12 US US15/838,605 patent/US20180369250A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,515 patent/US20200222413A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500939A1 (en) | Methods of treatment using selective bcl-2 inhibitors | |
| PH12018501827A1 (en) | Cancer treatment | |
| EA201290837A1 (ru) | Лечение волчаночного нефрита с применением лаквинимода | |
| MY172926A (en) | Tetrahydropyrazolopyrimidine compounds | |
| MD4635C1 (ro) | Compuşi de chinolină substituiţi selectiv | |
| EA201391329A1 (ru) | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) | |
| MX363708B (es) | Compuestos de quinolina selectivamente sustituidos. | |
| WO2012065102A8 (en) | S-t-butyl protected cysteine di-peptide analogs and related compounds | |
| MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
| MX355945B (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. | |
| MX2022001778A (es) | Metodos para tratar esquizofrenia. | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| BR112014011254A2 (pt) | 2-tiopirimidinonas | |
| MY159861A (en) | Formulations for use in sulfur scale control in industrial water systems | |
| CA2895138C (en) | Herbicidal agents containing aclonifen | |
| AU2011322715A8 (en) | Treatment of MeCP2-associated disorders | |
| WO2013013165A3 (en) | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus | |
| EA201491876A1 (ru) | Азотсодержащее бициклическое ароматическое гетероциклическое соединение | |
| BR112013003740A2 (pt) | composições algicidas sinergísticas incluindo derivados de hidrazona e cobre | |
| AU2011262991A1 (en) | Gemini virus replication inhibitor | |
| WO2008008841A3 (en) | Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders | |
| WO2011097027A3 (en) | Methods for treating or inhibiting infection by clostridium difficile | |
| MX2013002446A (es) | Derivados de tetrahidropirrolopirazina sustituidos. | |
| IN2013MU02290A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |